Topic

CRISPR

2 claims checked

SCIENCE Jul 11, 2026

Many CRISPR sickle cell trials edit BCL11A to boost fetal hemoglobin.

Claim: Many CRISPR-based sickle cell disease clinical trials primarily edit the BCL11A gene or its enhancer to reactivate fetal hemoglobin rather than directly repairing the HBB mutation. NOT BS

HEALTH Jul 11, 2026

Busulfan-based myeloablative conditioning is standard before reinfusing ex vivo CRISPR-edited stem cells.

Claim: Ex vivo CRISPR-based therapies for sickle cell disease typically require myeloablative conditioning with busulfan before reinfusion of edited hematopoietic stem cells. NOT BS